Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Population PK/PD and individualized mycophenolic acid dosing in lupus nephritis
ChiCTR2400086506Phase 4Not yet recruiting
- Sponsor
- Guizhou Provincial People's Hospital
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of mycophenolate mofetil and mycophenolic acid in lupus nephritis (LN) (2 arms), sponsored by Guizhou Provincial People's Hospital. Primary endpoints: Exposure of mycophenolic acid and Activity of inosine 5’-monophosphate dehydrogenase. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
mycophenolate mofetilmycophenolic acid
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on ChiCTR2400086506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086506.